Company plans to move REZPEG forward into Phase 2 clinical study in atopic dermatitis
SAN FRANCISCO, April 27, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will be regaining the full rights to REZPEG from Eli Lilly and Company.
Read more at prnewswire.com